AndroGel Pre-Surgery Hold Window: What Patients and Prescribers Need to Know

Why a Pre-Surgery Hold Exists for Testosterone Gel

Testosterone gel raises red blood cell mass in a dose-dependent fashion. Hematocrit climbs above 50% in roughly 5 to 7% of men on therapeutic doses of transdermal testosterone, and above 54% in a smaller subset. Polycythemia at those levels doubles whole-blood viscosity compared with a hematocrit of 42%, which matters enormously once a patient is lying still on an operating table for one to six hours.

Surgery itself compounds this. General anesthesia blunts the normal vasomotor responses that keep venous blood moving. Neuraxial blocks reduce lower-extremity muscle tone. Both conditions slow venous return from the legs, exactly the environment in which a high-hematocrit, high-viscosity blood column is most likely to clot.

The Polycythemia Mechanism

Testosterone stimulates erythropoiesis through two overlapping pathways. First, it directly stimulates erythropoietin production in the kidney. Second, it suppresses hepcidin, freeing more iron for hemoglobin synthesis. Research published in the Journal of Clinical Endocrinology and Metabolism confirmed that supraphysiologic and even high-normal testosterone levels are sufficient to raise EPO measurably within two weeks of starting therapy.

The gel formulation is not a low-risk exception. Because topical testosterone bypasses first-pass hepatic metabolism, it maintains serum levels continuously across 24 hours rather than producing the sharp peak-and-trough pattern of intramuscular injections. That sustained exposure drives erythropoiesis more consistently than weekly IM shots in some patients.

Thrombotic Risk Beyond Red Cells

Polycythemia is not the only concern. Testosterone also modulates platelet aggregation and coagulation factor levels. A 2019 meta-analysis in Thrombosis Research found that exogenous testosterone increased platelet aggregation response to ADP in six of eight included studies. The clinical significance in healthy, fully-mobile men appears modest. The significance shifts in a perioperative context where Factor VIII and fibrinogen are already elevated as part of the surgical stress response.

How Long to Hold AndroGel Before Surgery

The 10-to-14-day hold is the figure most commonly cited in perioperative endocrinology protocols and is the recommendation embedded in HealthRX clinical operating procedures.

Ten days reflects the time needed for serum testosterone levels to fall well below the high-normal range after cessation of daily gel application, combined with a partial reduction in erythrocyte mass. Fourteen days provides additional buffer in patients who entered the pre-op period with hematocrit above 50%.

Pharmacokinetic Basis for the 10-to-14-Day Window

AndroGel 1.62% applied at the labeled dose of 40.5 mg to 81 mg per day maintains mean steady-state serum testosterone between 400 and 700 ng/dL. Per the FDA-approved prescribing information, serum testosterone falls to below 300 ng/dL within 4 to 5 days of stopping application in most men.

However, hematocrit does not fall in parallel with serum testosterone. Red blood cells have a mean lifespan of 110 to 120 days. Stopping gel application removes the erythropoietic stimulus, but circulating red cells survive for months. A phlebotomy study in the journal Blood showed that even aggressive therapeutic phlebotomy takes 3 to 4 weeks to normalize hematocrit in polycythemia vera. Testosterone-induced erythrocytosis behaves similarly, though the degree is less severe.

The 10-to-14-day window is therefore a practical compromise: testosterone-driven new erythropoiesis stops, the acute thrombotic stimulus from high serum androgen levels is removed, and the patient is in the lowest-risk window achievable without scheduling surgery months out.

When the Standard Window Is Extended

Patients with hematocrit above 54% at the pre-op visit may require a longer hold, sometimes 3 to 4 weeks, or a single session of therapeutic phlebotomy targeting hematocrit below 50% before proceeding. The American Society of Hematology guidance on erythrocytosis supports phlebotomy to below 45% in high-thrombotic-risk scenarios, and some surgical teams apply that threshold pre-operatively.

Patients scheduled for procedures with high inherent VTE risk (hip or knee arthroplasty, major pelvic surgery, prolonged spine surgery) should have their hold period reviewed individually by the surgical team and the prescribing physician together.

Emergency Surgery Exception

For emergency procedures where a 10-day hold is not feasible, the anesthesia team should be informed of current AndroGel use and recent hematocrit values. The American Society of Anesthesiologists Task Force on Perioperative Blood Management recommends that a point-of-care hematocrit be obtained pre-induction in any patient on TRT who could not complete a standard hold period. Mechanical VTE prophylaxis intensity may be escalated accordingly.

The T-Trials Evidence Base

The T-Trials (Testosterone Trials) were a coordinated set of seven placebo-controlled trials enrolling 788 men aged 65 and older with low testosterone (below 275 ng/dL on two morning draws). Results were published in the New England Journal of Medicine in 2016. Men randomized to testosterone gel 1% saw mean serum testosterone rise from 232 ng/dL to 324 ng/dL at 3 months and to levels within the mid-normal range by 6 months.

Hematocrit Findings in T-Trials

Hematocrit rose significantly in the testosterone arm. The T-Trials cardiovascular sub-study reported that 7% of men in the testosterone group developed hematocrit above 54%, compared with 1% in the placebo group (P<0.001). This 7-fold relative increase in clinically significant erythrocytosis is the primary empirical basis for pre-surgical hematocrit screening in long-term AndroGel users.

The trial enrolled older men, who may be more susceptible to erythrocytosis than the broader TRT population. Younger men on testosterone gel are not immune, but the absolute rate of hematocrit above 54% in the general TRT population is closer to 2 to 3% based on real-world registry data.

Cardiovascular Safety Signal

The T-Trials cardiovascular trial showed a higher rate of coronary artery plaque volume increase in the testosterone arm. Specifically, non-calcified plaque volume increased by a mean of 41 mm3 in the testosterone group versus 17 mm3 in placebo (P<0.001). That finding does not directly change the hold-window calculation, but it reinforces why perioperative teams take androgen exposure seriously in older patients undergoing cardiac or major vascular procedures.

Labs to Check Before and After Surgery

A pre-operative laboratory panel for any patient on AndroGel should include, at minimum, a complete blood count with hematocrit, a basic metabolic panel, and a serum total testosterone drawn at least 4 hours after the last application if the patient did not complete the full hold.

Pre-Op Thresholds That Delay Elective Cases

• Hematocrit above 54%: most surgical centers require intervention (phlebotomy or extended hold) before proceeding with elective cases.
• Hematocrit 50 to 54%: proceed with caution; enhanced mechanical prophylaxis and pharmacologic VTE prophylaxis should be discussed.
• Hematocrit below 50%: standard perioperative VTE protocol applies; no additional testosterone-specific modification is typically required.

The Endocrine Society Clinical Practice Guideline on testosterone therapy states: "Clinicians should check hematocrit at baseline, at 3 to 6 months, and annually thereafter. If hematocrit exceeds 54%, testosterone should be stopped until hematocrit normalizes." That guideline language, while written for longitudinal management rather than perioperative care, is the standard most surgeons reference when setting pre-op hold criteria.

Post-Op Resumption

Most patients can resume AndroGel 24 to 48 hours after surgery once they are ambulating, tolerating oral intake, and off parenteral opioids (which slow gastrointestinal motility and can affect transdermal absorption indirectly through skin perfusion changes). There is no pharmacological reason to delay beyond 48 hours in an uncomplicated recovery.

A 2021 review in Urology Practice noted that prolonged post-operative testosterone interruption of more than 6 weeks is associated with symptomatic hypogonadism recurrence in men with confirmed secondary hypogonadism, including fatigue, loss of lean mass, and mood changes. Resuming promptly matters.

Transfer Risk and Application Site Safety Around Surgery

AndroGel carries a boxed warning about secondary exposure to women and children through skin contact. The FDA label requires application to the shoulders, upper arms, or abdomen (depending on formulation) and thorough hand washing post-application.

In the immediate post-operative period, application site selection matters for a different reason: surgical dressings, warming blankets, and ECG electrodes are frequently placed over the shoulders and upper chest. Applying gel under or near surgical dressings can alter absorption unpredictably and may transfer active drug to healthcare workers through routine wound care.

Practical Application Site Guidance Post-Surgery

Patients resuming AndroGel after discharge should avoid applying gel to any area covered by a wound dressing, surgical tape, or compression garment for the full duration of wound closure. The abdomen is typically the most accessible site in the first two weeks post-op for patients who had shoulder, chest, or back procedures.

Dosing Context: AndroGel 1% vs. 1.62%

AndroGel 1% delivers testosterone at 25 mg or 50 mg per day (2 or 4 pump actuations or 1 or 2 packets). AndroGel 1.62% delivers 20.25 mg to 81 mg per day depending on dose titration. The FDA prescribing information for AndroGel 1.62% notes that the higher-concentration formulation reaches steady state within 24 hours of the first dose because of the smaller application volume.

From a perioperative standpoint, the two formulations carry the same hold-window recommendation. The higher concentration does not require a longer hold; pharmacodynamic effects on erythropoiesis are driven by achieved serum testosterone level, not formulation concentration.

Patient Counseling Points

Patients often do not volunteer TRT use to surgical teams because they classify it as a "supplement" rather than a prescription medication. A 2018 survey in the Journal of Urology found that 22% of men on TRT did not disclose use when completing pre-operative medication histories. That non-disclosure rate is high enough to make active screening worthwhile.

What to Tell Patients at the Pre-Op Consult

The prescribing clinician should give patients a written note at the pre-op visit specifying:

1. The exact date to apply the last dose before surgery.
2. The instruction to inform the anesthesiologist and surgeon of current TRT use regardless of who is managing it.
3. The date on which it is safe to resume application after the procedure.
4. A reminder to have a CBC drawn at the 6-week post-op visit if the hold exceeded 3 weeks.

Patients who stop AndroGel abruptly sometimes experience withdrawal-like hypogonadal symptoms: fatigue, low mood, and reduced libido beginning 5 to 10 days after the last dose. Research in Clinical Endocrinology confirmed measurable drops in serum testosterone to below 200 ng/dL within 7 days of stopping daily transdermal therapy in men who had been on TRT for more than 12 months. Patients should be counseled that these symptoms are temporary and expected, not a sign of surgical complication.

Special Populations: Men With OSA or Sleep Disruption

Testosterone gel is relatively contraindicated in men with untreated obstructive sleep apnea (OSA) because it worsens nocturnal oxygen desaturation. A randomized study in JAMA Internal Medicine found that testosterone replacement worsened apnea-hypopnea index by a mean of 11 events per hour in men with moderate pre-existing OSA. Post-operative OSA is common due to residual anesthetic effects and opioid use, so resumption in men with known OSA should be discussed with the surgical team before the 24-to-48-hour standard window.

Monitoring Protocol Summary

The table below synthesizes current guidance into a practical perioperative timeline for patients on AndroGel.

| Timepoint | Action | |---|---| | 4 to 6 weeks pre-op | CBC, hematocrit, serum total testosterone; review hold plan | | 10 to 14 days pre-op | Last AndroGel application (standard hold) | | Day of surgery | Inform anesthesia of TRT use; point-of-care hematocrit if hold was shortened | | Post-op day 1 to 2 | Resume AndroGel if ambulating and tolerating oral intake | | 4 to 6 weeks post-op | Repeat CBC if hold exceeded 3 weeks; recheck serum testosterone | | 3 months post-op | Standard TRT monitoring visit per Endocrine Society guideline |

The American Urological Association guideline on testosterone deficiency recommends a minimum monitoring frequency of every 6 to 12 months for stable TRT patients, with more frequent checks whenever therapy is interrupted for more than 2 weeks. A perioperative hold qualifies as such an interruption.